BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35339994)

  • 1. [Therapeutic hypothermia-induced QT prolongation and “torsade de pointes” ventricular tachycardia].
    Tomcsányi J; Arányi P; Arabadzisz H
    Orv Hetil; 2022 Mar; 163(13):523-526. PubMed ID: 35339994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.
    Uvelin A; Pejaković J; Mijatović V
    J Anesth; 2017 Jun; 31(3):413-423. PubMed ID: 28229241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation.
    Gilmour RF; Riccio ML; Locati EH; Maison-Blanche P; Coumel P; Schwartz PJ
    J Am Coll Cardiol; 1997 Jul; 30(1):209-17. PubMed ID: 9207644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CME ECC 66: Torsade de Pointes: The Danger of a Rotating Heart Axis].
    Markendorf S; Saguner AM; Brunckhorst C
    Praxis (Bern 1994); 2020 Sep; 109(12):944-951. PubMed ID: 32933390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CME ECG 66/Answers: Torsade de Pointes: The Danger of a Rotating Heart Axis].
    Markendorf S; Saguner AM; Brunckhorst C
    Praxis (Bern 1994); 2020; 109(13):1035-1038. PubMed ID: 33050812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ECG pearl: acquired long QT syndrome].
    Tomcsányi J; Tomcsányi K
    Orv Hetil; 2018 Sep; 159(39):1607-1610. PubMed ID: 30543125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome.
    Halkin A; Roth A; Lurie I; Fish R; Belhassen B; Viskin S
    J Am Coll Cardiol; 2001 Oct; 38(4):1168-74. PubMed ID: 11583899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Torsade de pointes induced by terfenadine in a patient with long QT syndrome.
    Koh KK; Rim MS; Yoon J; Kim SS
    J Electrocardiol; 1994 Oct; 27(4):343-6. PubMed ID: 7815014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A practical approach to torsade de pointes.
    Roden DM
    Clin Cardiol; 1997 Mar; 20(3):285-90. PubMed ID: 9068917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Takotsubo Cardiomyopathy Presenting with QT Prolongation and Torsade de Pointes in a Patient with Coronavirus Disease 2019.
    Kawanaka H; Ogano M; Hibako K; Tanabe J
    J Nippon Med Sch; 2024 Mar; 91(1):124-128. PubMed ID: 36823121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QT interval prolongation and torsade de pointes.
    Patanè S; Marte F; Di Bella G
    Int J Cardiol; 2009 Jan; 131(2):e51-3. PubMed ID: 17689729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Torsade de pointes induced by ajmaline.
    Haverkamp W; Mönnig G; Kirchhof P; Eckardt L; Borggrefe M; Breithardt G
    Z Kardiol; 2001 Aug; 90(8):586-90. PubMed ID: 11565214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany.
    Elsayed M; Abdel-Kahaar E; Gahr M; Connemann BJ; Denkinger M; Schönfeldt-Lecuona C
    Eur J Clin Pharmacol; 2021 May; 77(5):767-775. PubMed ID: 33230596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Iatrogenic torsade de pointes induced by thioridazine].
    Paoloni P; Ciliberti D; Blasi N; Capone P
    Minerva Cardioangiol; 1992 Jun; 40(6):245-9. PubMed ID: 1407620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of short QT-interval postventricular arrhythmia arrest from Torsade De Pointes, a new phenotype, or the result of tachycardia-mediated imbalance.
    Ifedili I; Maturana M; Kayali S; Levine Y; Kabra R; Jha SK
    J Cardiovasc Electrophysiol; 2024 Mar; 35(3):501-504. PubMed ID: 38174843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.